Ocular Therapeutix (NASDAQ:OCUL) COO Donald Notman Sells 11,446 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) COO Donald Notman sold 11,446 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $103,471.84. Following the completion of the transaction, the chief operating officer directly owned 366,356 shares of the company’s stock, valued at $3,311,858.24. The trade was a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Donald Notman also recently made the following trade(s):

• On Wednesday, February 4th, Donald Notman sold 6,035 shares of Ocular Therapeutix stock. The stock was sold at an average price of $8.54, for a total value of $51,538.90.
• On Monday, February 2nd, Donald Notman sold 5,455 shares of Ocular Therapeutix stock. The stock was sold at an average price of $9.14, for a total value of $49,858.70.

Ocular Therapeutix Stock Down 21.3%

Ocular Therapeutix stock opened at $6.99 on Wednesday. Ocular Therapeutix, Inc. has a fifty-two week low of $5.78 and a fifty-two week high of $16.44. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -4.85 and a beta of 0.90. The stock’s fifty day moving average is $11.22 and its two-hundred day moving average is $11.78. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. The business had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The business’s revenue for the quarter was down 22.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.29) EPS. Analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, January 22nd. Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday. Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, February 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 price objective on shares of Ocular Therapeutix in a research note on Monday, December 8th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC increased its stake in Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,242 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new stake in Ocular Therapeutix in the 4th quarter worth about $42,000. Nisa Investment Advisors LLC grew its holdings in Ocular Therapeutix by 62.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,392 shares during the period. Atlas Capital Advisors Inc. acquired a new position in shares of Ocular Therapeutix during the 4th quarter valued at about $61,000. Finally, State of Wyoming acquired a new position in shares of Ocular Therapeutix during the 4th quarter valued at about $78,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
• Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron’s Eylea
• Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
• Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron’s leading Eylea

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.